Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05528666 · ClinicalTrials.gov registry record
Risk Perception in Multiple Sclerosis
A clinical trial of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4,361
- Enrollment target
- 1
- Study location
NCT05528666 is a study of Multiple Sclerosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,361 participants, above the 571-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (664% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05528666, a study of Multiple Sclerosis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4,361 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with RMS (RRMS and SPMS). Patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (HETs) and those who were prescribed with non-high efficacy treatments (non-HETs). HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod; and non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
Conditions Studied
Interventions
- OTHER High Efficacy Therapy (HET)
- OTHER Non High Efficacy Therapy (Non-HET)
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,361 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2021-09-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05528666
The ClinicalTrials.gov registry entry for NCT05528666 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,361 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 571-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (664% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which High Efficacy Therapy (HET) is the first listed.
NCT05528666 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05528666 about?
NCT05528666 is a clinical study titled "Risk Perception in Multiple Sclerosis". This study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with RMS (RRMS and SPMS). Patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (HETs) and ...
What is the current status of trial NCT05528666?
This trial is currently completed. The enrollment target is 4,361 participants. The study started on 2021-09-09. Estimated completion is 2021-09-17.
What conditions does trial NCT05528666 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT05528666?
The interventions under investigation include: High Efficacy Therapy (HET) (OTHER), Non High Efficacy Therapy (Non-HET) (OTHER).
Who is sponsoring clinical trial NCT05528666?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05528666 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.